for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

GlaxoSmithKline plc (ADR)

GSK.N

Latest Trade

34.70USD

Change

0.42(+1.23%)

Volume

725,596

Today's Range

34.34

 - 

34.84

52 Week Range

31.43

 - 

43.18

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Latest Developments

Morphosys Says Licensing Partner GSK Shared Prelim Results From OSCAR Study With Otilimab

March 2 (Reuters) - Morphosys Ag <MORG.DE>::DGAP-NEWS: MORPHOSYS'S LICENSING PARTNER GSK SHARED PRELIMINARY RESULTS FROM OSCAR STUDY WITH OTILIMAB FOR THE TREATMENT OF SEVERE PULMONARY COVID-19 RELATED DISEASE.EVENT OF FIRST PATIENT DOSED IN EXPANDED STUDY TRIGGERS MILESTONE PAYMENTS OF A TOTAL OF EUR 16 MILLION TO MORPHOSYS.EXPANDING STUDY FOR PATIENTS 70 YEARS AND OLDER.

EMA Says CHMP Endorses GSK's Dostarlimab For Treatment Of Advanced Endometrial Cancer

Feb 26 (Reuters) - European Medicines Agency (EMA)::EMA SAYS CHMP RECOMMENDED GRANTING A CONDITIONAL MARKETING AUTHORISATION FOR JEMPERLI (DOSTARLIMAB) FOR TREATMENT OF CERTAIN TYPES OF ENDOMETRIAL CANCER.EMA SAYS GENERIC MEDICINE ABIRATERONE ACCORD (ABIRATERONE) RECEIVED A POSITIVE OPINION FOR TREATMENT OF METASTATIC PROSTATE CANCER.Further company coverage: GSK.L. ((Reuters.Briefs@thomsonreuters.com;)).

Dodge & Cox Discloses 5.04% Stake In GSK As Of Feb. 19 - Filing

Feb 24 (Reuters) - Filing::GLAXOSMITHKLINE PLC - HOLDING(S) IN COMPANY.DODGE & COX DISCLOSES 5.04% STAKE IN GSK AS OF FEB. 19 - FILING.

Sanofi, GSK Start New Phase 2 Study Of Adjuvanted Recombinant Protein-Based COVID-19 Vaccine Candidate

Feb 22 (Reuters) - GlaxoSmithKline PLC <GSK.L>::GLAXOSMITHKLINE PLC - SANOFI AND GSK INITIATE NEW PHASE 2 STUDY.GSK - IN PARALLEL, DEVELOPMENT WORK ON NEW SARS-COV-2 VARIANTS UNDERWAY.GSK - NEW PHASE 2 STUDY ASSESSES POTENTIAL FOR REFINED ANTIGEN FORMULATION TO ACHIEVE OPTIMAL IMMUNE RESPONSE, INCLUDING IN OLDER ADULTS.GSK - IF RESULTS ARE POSITIVE, PHASE 3 STUDY TO START IN Q2 2021, WITH VACCINE EXPECTED TO BE AVAILABLE IN Q4 2021.GSK - DEVELOPMENT WORK ON NEW SARS-COV-2 VARIANTS UNDERWAY.GSK - SANOFI HAS COMMENCED DEVELOPMENT WORK AGAINST NEW VARIANTS WHICH WILL BE USED TO INFORM NEXT STAGES OF SANOFI/GSK DEVELOPMENT PROGRAMME..GSK - IN PARALLEL, DEVELOPMENT WORK ON NEW SARS-COV-2 VARIANTS UNDERWAY.

Sanofi, GSK Initiate New Phase 2 Study Of Their COVID-19 Vaccine Candidate

Feb 22 (Reuters) - Sanofi SA <SASY.PA>::REG-SANOFI AND GSK INITIATE NEW PHASE 2 STUDY OF THEIR ADJUVANTED RECOMBINANT PROTEIN-BASED COVID-19 VACCINE CANDIDATE.NEW PHASE 2 STUDY ASSESSES POTENTIAL FOR REFINED ANTIGEN FORMULATION TO ACHIEVE OPTIMAL IMMUNE RESPONSE, INCLUDING IN OLDER ADULTS.IF RESULTS ARE POSITIVE, PHASE 3 STUDY TO START IN Q2 2021, WITH VACCINE EXPECTED TO BE AVAILABLE IN Q4 2021.IN PARALLEL, DEVELOPMENT WORK ON NEW SARS-COV-2 VARIANTS UNDERWAY.

Gsk Starts Phase Iii Rsv Candidate Vaccine Programme For Older Adults

Feb 17 (Reuters) - :GSK STARTS PHASE III RSV CANDIDATE VACCINE PROGRAMME FOR OLDER ADULTS.GSK - POSITIVE PHASE I/II RESULTS FOR RSV VACCINE ESTABLISHED ROBUST IMMUNOGENICITY OF VACCINE CANDIDATE IN TARGET POPULATION.GSK - CANDIDATE VACCINE PART OF PORTFOLIO OF RSV VACCINES IN DEVELOPMENT, WHICH INCLUDES MATERNAL AND PAEDIATRIC VACCINE CANDIDATES.GSK - PHASE III STUDY OF RSV VACCINE EVALUATES IMMUNOGENICITY, SAFETY, REACTOGENICITY, PERSISTENCE, TO BE FOLLOWED BY SEPARATE STUDY FOR EFFICACY.GSK - EFFICACY STUDY FOR MATERNAL RSV CANDIDATE STARTED IN NOV., STUDY (IN RSV SERO-NAIVE INFANTS) WITH PAEDIATRIC RSV CANDIDATE IS ONGOING.

GSK And Vir Biotechnology Expand Coronavirus Collaboration To Advance New Therapeutics For Influenza And Other Respiratory Viruses

Feb 17 (Reuters) - GSK::GSK AND VIR BIOTECHNOLOGY EXPAND CORONAVIRUS COLLABORATION TO ADVANCE NEW THERAPEUTICS FOR INFLUENZA AND OTHER RESPIRATORY VIRUSES.EXPANDED COLLABORATION PROVIDES CO EXCLUSIVE RIGHTS TO COLLABORATE WITH VIR ON DEVELOPMENT OF POTENTIAL MONOCLONAL ANTIBODIES FOR INFLUENZA.CO TO HAVE EXCLUSIVE OPTION TO CO-DEVELOP VIR-2482 AFTER VIR COMPLETES AND REPORTS PHASE 2 TRIAL OUTCOMES.WILL MAKE AN UPFRONT PAYMENT OF $225 MILLION, AND A FURTHER EQUITY INVESTMENT IN VIR OF $120 MILLION.WILL SHARE DEVELOPMENT COSTS WITH VIR ON DEVELOPMENT OF ALL OTHER INFLUENZA MONOCLONAL ANTIBODIES.ADDITIONAL EXPLORATION WITH VIR OF UP TO THREE OTHER ANTIBODIES FOR PATHOGENS BEYOND INFLUENZA, CORONAVIRUS.IF GSK EXERCISES ITS OPTION TO CO-DEVELOP VIR-2482, AFTER COMPLETION OF PHASE 2 TRIALS, IT WILL PAY AN OPTION FEE OF $300 MILLION.

GSK, On Sandoz Deal, Says Proposes To Close Cephalosporins Manufacturing Ops

Feb 11 (Reuters) - GlaxoSmithKline PLC <GSK.L>::GSK, ON SANDOZ DEAL, SAYS PROPOSES TO CLOSE ITS CEPHALOSPORINS MANUFACTURING OPERATIONS ONCE TRANSFER OF MANUFACTURING OPERATIONS TO SANDOZ IS COMPLETE.GSK - IS PROVIDING SUPPORT TO POTENTIALLY AFFECTED EMPLOYEES.

Glaxosmithkline Majority Shareholder Decides To Focus On Transaction With Hikma Pharmaceuticals

Feb 8 (Reuters) - GLAXOSMITHKLINE SAE <BIOC.CA>::MAJORITY SHAREHOLDER DECIDES TO FOCUS ITS EFFORTS AND RESOURCES ON DISCUSSING TRANSACTION WITH HIKMA PHARMACEUTICALS AT THIS TIME.GLAXOSMITHKLINE SAYS GLAXO GROUP ARE NOT IN A POSITION TO ENGAGE WITH RAMEDA ON DISCUSSING A POTENTIAL TRANSACTION AT THIS TIME.GLAXO GROUP LIMITED ARE NOT IN A POSITION TO ENGAGE WITH ACDIMA EGYPT ON DISCUSSING A POTENTIAL TRANSACTION AT THIS TIME.

GSK Sees 2022 Aggregate Distributions Lower Than At Present

Feb 3 (Reuters) - GlaxoSmithKline PLC <GSK.L>::FINAL RESULTS.FY REVENUE 34.1 BILLION STG.FY EARNINGS PER SHARE ROSE 23 PERCENT TO 115.5 PENCE.2021 ADJUSTED EPS EXPECTED TO DECLINE BY A MID TO HIGH-SINGLE DIGIT PERCENTAGE IN CER.ON TRACK FOR SEPARATION INTO NEW STANDALONE BIOPHARMA AND CONSUMER HEALTHCARE COMPANIES IN 2022.DIVIDEND OF 23P/SHARE DECLARED FOR Q4 2020; 80P/SHARE FOR FY 2020.CONTINUE TO EXPECT MEANINGFUL IMPROVEMENT IN REVENUES AND MARGINS.2020 TARGETS MET WITH £0.3 BILLION ANNUAL COST SAVINGS AND £1.1 BILLION DIVESTMENT PROCEEDS ACHIEVED.DISTRIBUTION POLICY FOR NEW GSK TO BE IMPLEMENTED IN 2022 TO SUPPORT GROWTH AND INVESTMENT. AGGREGATE DISTRIBUTIONS EXPECTED TO BE LOWER THAN AT PRESENT.BIOPHARMA INVESTOR UPDATE IN JUNE TO SET OUT PROGRESS ON INNOVATION, COMMERCIAL EXECUTION, GROWTH OUTLOOK, CAPITAL ALLOCATION PRIORITIES.QTRLY TOTAL EPS WAS 13.6P.QTRLY VACCINES TURNOVER GREW 15% AER, 16% CER TO £2,012 MILLION, PRIMARILY DRIVEN BY DOUBLE-DIGIT GROWTH IN SHINGRIX.2022 OUTLOOK REMAINS UNCHANGED.NEW ENVIRONMENTAL TARGETS SET TO ACHIEVE NET ZERO IMPACT ON CLIMATE AND NET POSITIVE IMPACT ON NATURE BY 2030.PHARMACEUTICALS TURNOVER IN QUARTER WAS £4,366 MILLION, DOWN 4% AER, 3% CER.REPORTED CONSUMER HEALTHCARE SALES DECLINED 8% AER AND DECLINED 7% CER TO £2,360 MILLION IN QUARTER.IN A STRONG POSITION TO LAUNCH NEW COMPETITIVE, STANDALONE BIOPHARMA AND CONSUMER HEALTHCARE COMPANIES IN 2022.EXPECT STRONG RECOVERY AND CONTRIBUTION TO GROWTH FROM SHINGRIX IN SECOND HALF OF YEAR.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up